TITLE: TARGETING TROPOMYOSIN: DESIGN, SYNTHESIS AND SAR OF SOME FIRST-IN-CLASS CYTOSKELETON TARGETING SUBSTITUTED INDOLES IN CLINICAL DEVELOPMENT FOR A VARIETY OF CANCERS

First Page		Document Content
Cytoskeleton Proteins Muscular system Tropomyosin Cell biology Actin Microfilament Myosin		TITLE: TARGETING TROPOMYOSIN: DESIGN, SYNTHESIS AND SAR OF SOME FIRST-IN-CLASS CYTOSKELETON TARGETING SUBSTITUTED INDOLES IN CLINICAL DEVELOPMENT FOR A VARIETY OF CANCERS Add to Reading List Source URL: www.novogen.com Download Document from Source Website File Size: 1,18 MB Share Document on Facebook

	Anisina’s History of Community Support Novogen’s lead anti-tropomyosin (ATM) drug candidate, Anisina, is in the unusual position of having a history of strong community support throughout its development. The anti-tr DocID: 1s2fv - View Document
	ANTI-TROPOMYOSIN AGENTS ENHANCE THE ANTITUMOR EFFECTIVENESS OF MICROTUBULE INHIBITORS IN PRECLINICAL MODELS OF NEUROBLASTOMA. JUSTINE STEHN1,2, MARK CURRIER3, DUO CHEN3, BROOKE NARTKER3, ELEANOR EIFFE1, ANDREW HEATON1,2, DocID: 1qUPq - View Document
	Inquiry: The University of Arkansas Undergraduate Research Journal DocID: 1qKmX - View Document
	TITLE: TARGETING TROPOMYOSIN: DESIGN, SYNTHESIS AND SAR OF SOME FIRST-IN-CLASS CYTOSKELETON TARGETING SUBSTITUTED INDOLES IN CLINICAL DEVELOPMENT FOR A VARIETY OF CANCERS DocID: 1pmE5 - View Document
	ANISINA (ATMA potential new class of cytotoxic chemotherapy targeting the cytoskeleton  Preclinical studies show that Anisina enhances the killing effect of anti-microtubule drugs (taxanes and vinca alkaloids) DocID: 1ph49 - View Document